Compare FEAM & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEAM | GANX |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.2M | 78.2M |
| IPO Year | N/A | 2021 |
| Metric | FEAM | GANX |
|---|---|---|
| Price | $1.57 | $1.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.38 | ★ $7.50 |
| AVG Volume (30 Days) | 240.3K | ★ 688.3K |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $1.41 |
| 52 Week High | $7.50 | $4.34 |
| Indicator | FEAM | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 40.28 |
| Support Level | $1.45 | N/A |
| Resistance Level | $1.80 | $2.10 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 6.90 | 17.35 |
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.